- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Padmanabhan discusses impact of COVID-19
Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.
Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic. Dr. Padmanabhan was interviewed on April 17.
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
